Targeting CPT1A-Induced RAD51 Succinylation Overcomes DNA Repair-Mediated Temozolomide Resistance in Glioblastoma
Year: 2026
Type: preprint
Abstract: Background Temozolomide (TMZ) resistance in glioblastoma (GBM) is largely driven by enhanced DNA repair, but the contribution of mitochondrial metabolism and post-translational modifications remains unclear. Methods Integrated multi-omics were performed on TMZ-sensitive and resistant GBM cells. Succinylation sites were mapped by mass spectrometry; the succinyltransferase was identified via co-IP and in vitro assays. Mechanistic studies used mutagenesis, ubiquitination/degradation assays, and homologous recombination (HR) reporters. Pharmacological inhibition and a natural compound disrupting CPT1A–RAD51 were tested in orthotopic xenografts. Clinical relevance was evaluated in two patient cohorts. Results Resistant cells exhibited elevated α-ketoglutarate and succinate, expanding the succinyl-CoA pool. This rewiring drove RAD51 succinylation at K156, catalyzed by CPT1A—a novel succinyltransferase. K156 succinylation antagonized STUB1-dependent K48-linked ubiquitination at K216, protecting RAD51 from degradation and enhancing HR repair. CPT1A inhibition reduced RAD51 succinylation, impaired DNA repair, and restored TMZ sensitivity in vitro and in vivo. A natural compound disrupting the CPT1A–RAD51 interaction potently sensitized GBM to TMZ in vivo. Clinically, elevated RAD51 K156 succinylation correlated with poor prognosis and TMZ resistance. Conclusions We define a metabolic–epigenetic axis—TCA/succinyl-CoA/CPT1A/RAD51 K156 succinylation—that governs DNA repair and chemoresistance in GBM. CPT1A emerges as a therapeutic target, and RAD51 K156 succinylation serves as a promising prognostic biomarker for overcoming TMZ resistance.
Source: Research Square
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236459825
